Invivyd rises after unveiling promising new antibody for children
24/11/2025 12:50
** Shares of drugmaker Invivyd IVVD.O rise 2% to $2.55 premarket ** Company says it identifies a new antibody, VBY329, designed to prevent respiratory syncytial virus or RSV infections in newborns, infants and children ** RSV is a virus that can cause serious lung infections in infants ** Lab tests show VBY329 works better than company's current medicines nirsevimab and clesrovimab - IVVD ** It also fights RSV strains that no longer respond to nirsevimab, company says ** Drug is designed to stay longer in the body, which may give babies longer protection - IVVD ** Up to last close, shares have jumped more than fivefold YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview